menu
    • menu
    [{"orgOrder":0,"company":"Strata Oncology","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Strata Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Strata Oncology \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Strata Oncology \/ Gilead Sciences"},{"orgOrder":0,"company":"Strata Oncology","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Strata Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Strata Oncology \/ Mirati Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Strata Oncology \/ Mirati Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Strata Oncology

    Menu

    Strata Oncology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Strata Oncology

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed

                            Strata Oncology

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Gilead Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Strata Oncology Announces Addition of Gilead as Strata PATH Trial Collaborator

                            Details : Under the terms of collaboration, Gilead will supply TRODELVY (sacituzumab govitecan-hziy) for prospective, pan-tumor trial. Trodelvy is an antibody-drug conjugate immune targeted therapy indicated for unresectable locally advanced or metastatic triple- ...

                            Product Name : Trodelvy

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            January 18, 2023

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Gilead Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Strata Oncology

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed

                            Strata Oncology

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adagrasib,Cetuximab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Mirati Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Strata Oncology Announces Partnership to Broaden Enrollment in Mirati Therapeutics' Clinical Trial of MRTX849

                            Details : Under the terms of the agreement, Strata Oncology will identify patients with advanced solid tumors who have a KRAS G12C mutation and meet other eligibility criteria, to be considered for enrollment into Mirati's Phase 1/2 study, MRTX849-001 a G12C selec...

                            Product Name : MRTX849

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 13, 2020

                            Lead Product(s) : Adagrasib,Cetuximab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Mirati Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth